Status:
SUSPENDED
Microbiome Therapy in Covid-19 Primary Care Support
Lead Sponsor:
University Hospital, Antwerp
Conditions:
SARS-CoV Infection
Corona Virus Infection
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This double-blind, randomized, placebo-controlled study aims to investigate whether a throat spray containing probiotic bacteria (i.e. microbiome spray) can reduce the symptoms and complaints of the S...
Eligibility Criteria
Inclusion
- Patients in primary care with a positive SARS-CoV-2 test based on PCR
- Instructed during screening and agreed not to use other probiotic nutritional supplements outside of the study during the study period
- Sign the consent form
Exclusion
- Antibiotic use at baseline and during the study
- Vaccinated against SARS-CoV-2 at start of the study (both for index patients and household members that participate)
- Pregnant women
- History of use of probiotic supplements in the past two weeks
- Current diagnosis of cancer or immunosuppressive therapy within the past 6 months
- Acute and chronic infectious and inflammatory upper airway diseases (eg acute / chronic rhinosinusitis)
- Clinically significant bleeding disorder
- Any other medical condition that, in the principal investigator's opinion, warrants exclusion from the trial
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04793997
Start Date
February 1 2021
End Date
February 1 2022
Last Update
June 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Veronique Verhoeven
Antwerp, Belgium, 2020